Connect with us

Technology

In-Vitro Diagnostics Instruments Market size is set to grow by USD 52.9 billion from 2024-2028, Growing geriatric population boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global in-vitro diagnostics instruments market size is estimated to grow by USD 52.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.29% during the forecast period. Growing geriatric population is driving market growth, with a trend towards potential opportunities for physician office laboratories (POL). However, strained laboratory budgets and lowering reimbursements affecting instrument sales poses a challenge. Key market players include Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

In-Vitro Diagnostics Instruments Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 – 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.29%

Market growth 2024-2028

USD 52.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.25

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 33%

Key countries

US, Germany, China, Canada, and UK

Key companies profiled

Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.

 

Market Driver

In-Vitro Diagnostics (IVD) instruments market growth is driven by the increasing adoption of Point of Care (POL) testing in primary and outpatient care. POL testing, particularly in infectious disease markers, cardiovascular diseases, and diabetes care, is gaining popularity due to its convenience and quick results. Portable IVD instruments are advancing technically, enabling clinicians to perform tests in-house. The CLIA testing for molecular assays in POL practices is expected to fuel market growth. However, certain regulatory aspects regarding CLIA-waived testing may impact market expansion. Despite these challenges, the global IVD instruments market is projected to experience average growth due to the increasing trend towards POL testing. 

The In Vitro Diagnostics Instruments Market is experiencing significant growth due to the rising demand for accurate and rapid medical tests. With a focus on infectious diseases such as Malaria and Chikungunya, the market is seeing increased adoption of advanced technologies like Next-Generation Sequencing (NGS) for pathogen detection. Laboratory technicians play a crucial role in this sector, handling various samples like blood, serum, plasma, urine, saliva, and tissues. Blood banks, home care settings, pharmaceutical companies, biotechnology firms, academic institutes, and non-communicable disease segments are key end-users. Infectious diseases and chronic conditions including cardiology, gastroenterology, and cancer are major application areas. The aging population and the rise of molecular diagnostics for diseases like Alzheimer’s and various cancers further fuel market expansion. In vitro diagnostics instruments offer efficiency, accuracy, and convenience in the laboratory environment, making them an essential tool for healthcare providers. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

In the In-Vitro Diagnostics Instruments Market, reimbursement policies for diagnostic testing vary across geographies and are trending downward. This puts pressure on hospitals and diagnostic laboratories to reduce expenditure on IVD instruments to maintain revenue. Workforce shortages and lost health insurance cards lead to fewer patient visits and limited testing volumes. Lean laboratories are emerging in some countries, prioritizing essential capital equipment purchases. Reduced reimbursements for certain instruments, such as SMBG in Europe and IVD instruments in the US, impact sales growth. IVD companies respond by focusing on emerging markets and adapting to market conditions. These factors are expected to restrict the growth of the global IVD Instruments Market during the forecast period.The In-Vitro Diagnostics (IVD) Instruments Market is experiencing significant growth due to advances in Next Generation Sequencing, Liquid Biopsy, and Personalized Medicine. Genetic and molecular diagnostic technologies are driving innovation in Clinical Profiles, Companion Diagnostics, and various disease areas such as Hospitals and Healthcare Facilities. IVD equipment in Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, and Cardiac Diseases are in high demand. Challenges include Norovirus, HIV, Lyme disease, and other infectious diseases. Reagents and kits, Software and Services, and Manufacturing Technology are essential components of this market. Diabetes, Oncology, Sexually Transmitted Diseases, and Geriatric Population are key applications. Distribution channels include hypermarkets, pharmacies, drug stores, online providers, standalone laboratories, and Clinical Laboratories. Tropical diseases and Endocrine Disorders are also targeted markets. High blood cholesterol, Heart Disease, Stroke, and Chronic Conditions are significant disease areas.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This in-vitro diagnostics instruments market report extensively covers market segmentation by 

Product 1.1 Immunochemistry1.2 Clinical microbiology1.3 Molecular diagnostics1.4 OthersEnd-user 2.1 Hospitals and diagnostic laboratories2.2 Academic and research institutes2.3 Home careGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Immunochemistry- The In-Vitro Diagnostics (IVD) Instruments Market’s highly automated segment of clinical laboratories holds the largest test volume compared to others. However, the demand for immunochemistry analyzers is declining in the US and Europe due to consolidation in France, late payments from Italy, Spain, and Portugal, and reductions in expenditure in the UK, France, and Germany. In contrast, the rise of rural hospitals in China and India lacking basic diagnostics infrastructure presents a growth opportunity. Over 80 immunoassay analyzer models are available, with manufacturers responding to competition through frequent new launches or analyzer upgrades. Reduced European reimbursement is attributed to delayed spending by some medical laboratories, while the Affordable Care Act (ACA) provides greater certainty for investments. IVDs, like Ortho Clinical Diagnostics’ VITROS immunodiagnostic products for HIV-1+2 detection, aid in early COVID-19 virus detection. Roche Diagnostics received FDA approval for the first HIV-1/HIV-2 qualitative test on cobas 6800/8800 systems. Innovative products and advanced technologies continue to enter the market, intensifying competition during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

In vitro diagnostics refer to medical tests conducted outside of a living organism, using samples of bodily fluids, tissues, or other specimens. These tests play a crucial role in the detection and diagnosis of various diseases, including infectious diseases such as Zika, Malaria, and Chikungunya, as well as chronic conditions like cardiovascular diseases, cancer, and endocrine disorders. The laboratory environment is essential for the accurate and reliable performance of these tests. In vitro diagnostics are used extensively in clinical laboratories to diagnose non-communicable diseases such as heart disease, stroke, high blood cholesterol, and Alzheimer’s disease. Molecular diagnostics and pathogen detection are advanced areas of in vitro diagnostics, offering rapid and accurate results for the diagnosis of various conditions. Laboratory technicians play a vital role in the collection, preparation, and analysis of samples for in vitro diagnostic tests. In vitro diagnostics are used in various medical specialties, including cardiology, gastroenterology, and neurology, to aid in the early detection and treatment of diseases.

Market Research Overview

In Vitro Diagnostics Instruments Market: Overview The In Vitro Diagnostics Instruments Market refers to the industry that produces and supplies diagnostic tools and equipment used in medical laboratories for analyzing samples derived from bodily fluids, tissues, and other specimens. These diagnostic instruments play a crucial role in detecting various diseases, including infectious diseases such as Norovirus, HIV, Lyme disease, and Shigellosis, chronic conditions like diabetes, cardiovascular diseases, cancer, and Alzheimer’s disease, and genetic disorders. The market caters to various end-users, including hospitals, healthcare facilities, pharmacies, drug stores, online providers, standalone laboratories, and clinical laboratories. The In Vitro Diagnostics Instruments Market encompasses a wide range of diagnostic technologies, including Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and others. The market is segmented into various product categories, including IVD equipment, Diagnostic Technologies, Reagents and Kits, Software and Services, and Molecular Diagnostics. Molecular Diagnostics further includes Next-Generation Sequencing (NGS), Liquid Biopsy, and Personalized Medicine. The market is also influenced by various factors such as the aging population, the rise in non-communicable diseases, and the increasing prevalence of chronic conditions. The In Vitro Diagnostics Instruments Market is driven by the growing demand for early and accurate diagnosis, the increasing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies such as NGS, liquid biopsy, and companion diagnostics. The market is also expected to witness significant growth due to the increasing prevalence of diseases such as diabetes, cancer, and cardiovascular diseases, and the growing awareness and acceptance of genetic testing. The market is highly competitive, with various players offering a wide range of diagnostic instruments and solutions. The market is also witnessing significant innovation, with new technologies and products being developed to address the evolving needs of healthcare providers and patients. Some of the key trends in the market include the increasing use of automation, the integration of artificial intelligence and machine learning, and the growing focus on point-of-care testing. The In Vitro Diagnostics Instruments Market is expected to grow at a significant CAGR during the forecast period, driven by the increasing demand for accurate and timely diagnosis, the growing prevalence of chronic diseases, and the increasing adoption of advanced diagnostic technologies. The market is also expected to be influenced by various factors such as regulatory frameworks, reimbursement policies, and technological advancements. In conclusion, the In Vitro Diagnostics Instruments Market plays a vital role in the healthcare industry by providing accurate and timely diagnosis, enabling personalized medicine, and contributing to better patient outcomes. The market is highly dynamic and is expected to witness significant growth in the coming years, driven by various factors such as the increasing prevalence of chronic diseases, the growing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductImmunochemistryClinical MicrobiologyMolecular DiagnosticsOthersEnd-userHospitals And Diagnostic LaboratoriesAcademic And Research InstitutesHome CareGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-vitro-diagnostics-instruments-market-size-is-set-to-grow-by-usd-52-9-billion-from-2024-2028–growing-geriatric-population-boost-the-market-technavio-302210037.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Bit Digital, Inc. Secures Site for New Tier 3 Data Center to Support Cerebras Colocation Contract

Published

on

By

NEW YORK, April 11, 2025 /PRNewswire/ — Bit Digital, Inc. (Nasdaq: BTBT) (“Bit Digital” or the “Company”) announced today that it has secured the rights to a new data center site in Saint-Jérôme, Québec (“MTL-3“), which is under development and will support the previously announced 5MW colocation agreement with Cerebras Systems (“Cerebras”), a leader in generative AI infrastructure.

The facility spans approximately 202,000 square feet on 7.7 acres and is being developed to support current contracted capacity, with future expansion potential subject to utility approvals. The transaction was executed under a lease-to-own structure, which includes a fixed-price purchase option exercisable within 12 months. The lease term is 20 years, with two 5-year extension options.

The project is being delivered through WhiteFiber, Bit Digital’s high-performance computing platform. The facility is being retrofitted to Tier 3 standards, with development costs expected to total approximately CAD $55 million (approximately $40MM USD), and a targeted go-live date of July 2025.

“This milestone represents continued momentum in our strategy to deliver purpose-built AI infrastructure at scale,” said Sam Tabar, CEO of Bit Digital. “Speed to market is a key differentiator in the AI infrastructure space, and this site reflects our ability to mobilize and deliver capacity on accelerated timelines. We’re proud to advance our partnership with Cerebras while expanding our data center footprint in the greater Montréal region, a growing hub for AI innovation.”

Cerebras has contracted for 5MW (IT load) of built-to-suit infrastructure under a five-year colocation agreement announced in February 2025. Under the terms of the agreement, Cerebras holds a right of first refusal (ROFR) for any additional megawatt capacity that becomes available at the site.

About Bit Digital

Bit Digital, Inc. is a global platform for high-performance computing (“HPC”) infrastructure and digital asset production headquartered in New York City. The Company’s HPC business operates under the WhiteFiber Inc. (“WhiteFiber”) brand. Our operations are located in the US, Canada, and Iceland. For additional information, please contact ir@bit-digital.com or visit our website at www.bit-digital.com, or follow us on LinkedIn or X.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 (Annual Report). Notwithstanding the fact that Bit Digital Inc. has not conducted operations in the PRC since September 30, 2021 we have previously disclosed under Risk Factors in our Annual Report: “We may be subject to fines and penalties for any noncompliance with or any liabilities in our former business in China in a certain period from now on.” Although the statute of limitations for non-compliance by our former business in the PRC is generally two years and the Company has been out of the PRC, for more than two years, the Authority may still find its prior bitcoin mining operations involved a threat to financial security. In such event, the two-year period would be extended to five years. If any material risk was to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. Future changes in the network-wide mining difficulty rate or bitcoin hash rate may also materially affect the future performance of Bit Digital’s production of bitcoin. Actual operating results will vary depending on many factors including network difficulty rate, total hash rate of the network, the operations of our facilities, the status of our miners, and other factors. See “Safe Harbor Statement” below.

Safe Harbor Statement

This press release may contain certain “forward-looking statements” relating to the business of Bit Digital, Inc., and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bit-digital-inc-secures-site-for-new-tier-3-data-center-to-support-cerebras-colocation-contract-302426047.html

SOURCE Bit Digital, Inc.

Continue Reading

Technology

Cipriani & Werner Cybersecurity Welcomes Five Attorneys

Published

on

By

PHILADELPHIA, April 11, 2025 /PRNewswire/ — Cipriani & Werner, P.C. is pleased to announce the addition of five attorneys to the firm’s Cybersecurity Breach & Litigation Practice Group. Joining the firm’s Philadelphia office are Kevin Mekler (Partner), James Cope (Partner), Tara Gill Nalencz (Partner), Jack Dunn (Associate), and Morgan Valeo (Associate).

“We are excited to continue investing in great lawyers to add to Cipriani & Werner’s already deep bench,” said John Loyal, co-chair of the firm’s Cybersecurity practice. “Each is a seasoned counselor who will slide seamlessly into the wonderful team we have built.”

Kevin Mekler has broad experience with all aspects of cybersecurity incident response and guides organizations of all shapes and sizes through the process, from initial triage and investigation through performance of legal and regulatory obligations the organizations may have.James Cope has been on the front lines of breach incident response for nearly a decade. He manages all aspects of data privacy and cyber security matters from start to finish. He has helped hundreds of entities around the country assess and respond to all types of data privacy and cybersecurity issues.Tara Gill Nalencz is a trial lawyer skilled in handling complex litigation from inception through to verdict and appeal. She defends clients in high-exposure, multifaceted matters, including privacy class actions. She provides crisis management counsel and response strategies for critical incidents and emergencies.Jack Dunn comes to Cipriani & Werner from Travelers where he coordinated and supported incident response between insureds, breach counsel, and forensic vendors for ransomware matters, social engineering frauds, business email compromises, and third-party data breaches.Morgan Valeo is a breach coach for clients victimized by data privacy and security incidents, such as a business email compromise, ransomware, wire transfer fraud and other network intrusions. She routinely works with external and third-party forensic investigation firms to determine the nature and scope of the incident and then to identify the legal, regulatory, and contractual obligations the victim organization has stemming from the incident.

In just five years, Cipriani & Werner’s Cybersecurity Breach & Litigation Practice Group has grown to over seventy team members. The group is the firm’s fastest growing practice group and is one of the go-to firms for data security incidents in the United States. 

About Cipriani & Werner, P.C.

Cipriani & Werner’s Cybersecurity team helps clients with all aspects of data breach preparation and response. Reach the Cyber team 24/7 by contacting 1-833-63-CYBER or cwcyber@c-wlaw.com. Cipriani & Werner is a multidisciplinary law firm with more than two hundred professionals in eighteen offices serving a global client base.

View original content:https://www.prnewswire.com/news-releases/cipriani–werner-cybersecurity-welcomes-five-attorneys-302426210.html

SOURCE Cipriani & Werner, P.C.

Continue Reading

Technology

DeepL Named to Forbes’s AI 50 List for Second Consecutive Year

Published

on

By

Trusted by 200,000+ businesses worldwide, DeepL recognized as a leader in AI-powered translation and writing solutions

NEW YORK, April 11, 2025 /PRNewswire/ — DeepL, a leading global Language AI company, has been named to Forbes’ 2025 AI 50 list for the second year in a row, which spotlights the most promising companies applying artificial intelligence to solve real-world challenges across industries. Compiled in partnership with Sequoia Capital and Meritech Capital, this year’s list was one of the most competitive yet, with Forbes reviewing over 1,860 submissions.

“DeepL being named to the Forbes AI 50 list for the second year running is a huge honor,” said Jarek Kutylowski.

“Being named to the Forbes AI 50 list for the second year running is a huge honor,” said Jarek Kutylowski, CEO and Founder, DeepL. “This recognition reflects the very real impact that DeepL’s language AI platform is driving for businesses and professionals around the world – helping them scale and collaborate more effectively across languages and markets. It also underscores our commitment to staying ahead of the curve through constant innovation. We’re proud to be a leader in Language AI and look forward to continuing to drive the category forward.”

As businesses adopt AI, they’re looking for solutions with impact and DeepL’s Language AI platform has become a critical investment for global success by tackling one of the biggest obstacles to business growth: language and communication barriers. Purpose-built for businesses and professionals, DeepL’s secure, specialized platform offers advanced translation and writing tools spanning written and spoken translation, AI-powered writing support, and a robust API, helping organizations communicate more clearly across countless use cases, from internal operations to customer support.

Today, DeepL is the preferred Language AI platform for businesses worldwide with a rapidly expanding customer network of over 200,000 businesses and governments including industry leaders Softbank, Mazda, Harvard Business Publishing, The Ifo Institute, Panasonic Connect and more. The company was recently ranked the #3 most popular AI tools globally, based on analysis by ZDNET, ahead of companies including Perplexity AI, Google Translate, Gemini, and Deepseek.

This recognition adds to DeepL’s ongoing streak of rapid growth and industry momentum. DeepL was just recognized by Fast Company as one of the Most Innovative Companies of 2025, ranking #5 in the Applied AI category. Over the past year, DeepL has also introduced several major product updates, including Clarify – an interactive feature that resolves ambiguities and offers more precise control over translations – and DeepL Voice, its first-ever live voice translation solution. DeepL also raised $300 million in new funding at a $2 billion valuation, expanded its US footprint with a new New York City tech hub, and much more.

To learn more about DeepL, visit https://www.deepl.com/en/whydeepl.

About DeepL

DeepL is on a mission to break down language barriers for businesses everywhere. Over 200,000 businesses and governments and millions of individuals across 228 global markets trust DeepL’s Language AI platform for human-like translation in both written and spoken formats, as well as natural, improved writing. Designed with enterprise security in mind, companies around the world leverage DeepL’s AI solutions that are specifically tuned for language to transform business communications, expand markets and improve productivity. Founded in 2017 by CEO Jaroslaw (Jarek) Kutylowski, DeepL today has over 1,000 passionate employees and is supported by world-renowned investors including Benchmark, IVP and Index Ventures. For more information, visit deepl.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/deepl-named-to-forbess-ai-50-list-for-second-consecutive-year-302426438.html

SOURCE DeepL

Continue Reading

Trending